Epelsiban
- Generic Name
- Epelsiban
- Drug Type
- Small Molecule
- Chemical Formula
- C30H38N4O4
- CAS Number
- 872599-83-2
- Unique Ingredient Identifier
- T2EZ19HX73
- Background
Epelsiban has been investigated for the treatment of Premature Ejaculation.
Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02794467
- Locations
- 🇺🇸
GSK Investigational Site, Houston, Texas, United States
Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women Volunteers
Phase 1
Completed
- Conditions
- Embryo Transfer
- Interventions
- Drug: Placebo to match GSK557296
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 31
- Registration Number
- NCT02703181
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female Volunteers
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT02257359
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban
Phase 1
Terminated
- Conditions
- Embryo Transfer
- Interventions
- First Posted Date
- 2014-08-11
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 33
- Registration Number
- NCT02213029
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath